Better Long-Term Buy: This Emerging Player or the Industry Leader? [Yahoo! Finance]
Prediction: This Healthcare Stock Could Soar by 72% in 2026 [Yahoo! Finance]
Abivax (NASDAQ:ABVX) had its price target raised by analysts at Morgan Stanley from $101.00 to $145.00. They now have an "overweight" rating on the stock.
Abivax (NASDAQ:ABVX) was given a new $131.00 price target on by analysts at Oppenheimer Holdings, Inc..
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..